Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

ABBV

Abbvie Inc

Oct 30 • 12:24PM ET

228.64

+3.50 1.56 %

Healthcare • Drug Manufacturers - General • USA • NYSE

Peers: JNJ PFE MRK LLY BMY GILD AMGN REGN VRTX BIIB

| Held by: VTI VOO IVV SPY VTV SCHD XLV VIG VYM IWF

Scroll to Statements

Index	S&P 500	P/E	108.81	EPS (ttm)	2.10	Insider Own	0.10%	Shs Outstand	1.77B	Perf Week	0.17%
Market Cap	403.91B	Forward P/E	15.80	EPS next Y	14.48	Insider Trans	-3.05%	Shs Float	1.76B	Perf Month	-6.44%
Enterprise Value	467.97B	PEG	6.34	EPS next Q	1.77	Inst Own	74.32%	Short Float	1.02%	Perf Quarter	17.12%
Income	3.72B	P/S	6.92	EPS this Y	3.87%	Inst Trans	0.11%	Short Ratio	3.37	Perf Half Y	18.26%
Sales	58.33B	P/B	-	EPS next Y	37.70%	ROA	2.67%	Short Interest	18.08M	Perf YTD	28.67%
Book/sh	-0.10	P/C	62.46	EPS next 5Y	17.15%	ROE	112.90%	52W High	244.81 -6.60%	Perf Year	20.54%
Cash/sh	3.66	P/FCF	22.15	EPS past 3/5Y	-28.18% -14.67%	ROIC	5.93%	52W Low	163.81 39.58%	Perf 3Y	52.61%
Dividend Est.	6.53 (2.86%)	EV/EBITDA	17.49	Sales past 3/5Y	0.08% 11.11%	Gross Margin	70.97%	Volatility	1.32% 1.87%	Perf 5Y	171.10%
Dividend TTM	6.56 (2.87%)	EV/Sales	8.02	EPS Y/Y TTM	-29.75%	Oper. Margin	31.61%	ATR (14)	3.92	Perf 10Y	373.67%
Dividend Ex-Date	Oct 15, 2025	Quick Ratio	0.61	Sales Y/Y TTM	6.05%	Profit Margin	6.38%	RSI (14)	53.71	Recom	1.90
Dividend Gr. 3/5Y	5.81% 7.46%	Current Ratio	0.74	EPS Q/Q	-31.76%	SMA20	-0.36%	Beta	0.49	Target Price	240.28
Payout	263.15%	Debt/Eq	-	Sales Q/Q	6.65%	SMA50	2.90%	Rel Volume	0.59	Prev Close	225.14
Employees	55000	LT Debt/Eq	-	Earnings	Oct 31 BMO	SMA200	14.71%	Avg Volume	5.37M	Price	228.64
IPO	Dec 10, 2012	Option/Short	Yes / Yes	EPS/Sales Surpr.	3.12% 2.62%	Trades		Volume	1,497,184	Change	1.56%

Date	Action	Analyst	Rating Change	Price Target Change
Oct-14-25	Downgrade	Erste Group	Buy → Hold
Oct-01-25	Downgrade	HSBC Securities	Buy → Hold
Sep-17-25	Upgrade	Berenberg	Hold → Buy	$270
Aug-12-25	Resumed	Piper Sandler	Overweight	$231
Aug-07-25	Upgrade	Daiwa Securities	Neutral → Outperform	$214
May-14-25	Downgrade	Citigroup	Buy → Neutral	$205
Apr-22-25	Initiated	Cantor Fitzgerald	Overweight	$210
Dec-10-24	Resumed	BofA Securities	Neutral	$191
Dec-05-24	Downgrade	Daiwa Securities	Outperform → Neutral	$180
Nov-22-24	Upgrade	Leerink Partners	Market Perform → Outperform	$206
Nov-15-24	Initiated	Wolfe Research	Outperform	$205
Nov-04-24	Upgrade	Argus	Hold → Buy
Oct-17-24	Initiated	Bernstein	Mkt Perform	$203
Jun-05-24	Upgrade	HSBC Securities	Hold → Buy	$185
May-17-24	Initiated	Cantor Fitzgerald	Overweight	$200
Jan-29-24	Upgrade	William Blair	Mkt Perform → Outperform
Dec-18-23	Downgrade	HSBC Securities	Buy → Hold
Dec-11-23	Upgrade	Goldman	Neutral → Buy
Nov-09-23	Initiated	Deutsche Bank	Hold	$150
Oct-30-23	Upgrade	Barclays	Equal Weight → Overweight	$160 → $170

Show Previous Ratings

Today 08:32AM	AbbVie posts another win for Rinvoq in Phase III vitiligo trials (Clinical Trials Arena)
05:47AM	Amazon, Apple Earnings, ECB Rate Decision: Still to Come This Week (The Wall Street Journal)
Oct-29-25 11:01PM	AbbVie (ABBV) Reports Earnings Tomorrow: What To Expect (StockStory)
05:00PM	The One & Only BOTOX Cosmetic (onabotulinumtoxinA) Day Returns November 19 with the Biggest Celebration of the Year (PR Newswire)
03:08PM	Trump Administration Eases Approval Process for Biosimilar Drugs (Barrons.com)
08:11AM	Loading…
08:11AM	AbbVie Announces Positive Topline Results from Phase 3 Pivotal Studies Evaluating Upadacitinib (RINVOQ) in Adults and Adolescents with Vitiligo (PR Newswire)
Oct-28-25 11:35AM	3 Cancer-Focused Stocks Showing Strong Pipeline Progress (Zacks)
10:00AM	Earnings Preview: Pfizer (PFE) Q3 Earnings Expected to Decline (Zacks)
09:00AM	Allergan Aesthetics and Girls Inc., in Partnership with SkinSpirit, Inspire Future Women Leaders in STEM (PR Newswire)
08:48AM	Should You Buy AbbVie Stock Ahead of Q3 Earnings Report? (Zacks)
06:26AM	Billionaire Israel "Izzy" Englander Has Loaded Up on This Dividend King. Should You? (Motley Fool)
Oct-27-25 11:05AM	What's in Store for These 5 Pharma Bigwigs This Earnings Season? (Zacks)
Oct-26-25 11:21AM	Prediction: These Dividend Stocks Could Outperform Growth Stocks in the Next Decade (Motley Fool)
Oct-24-25 07:45PM	AI Chatbots Were Told to Trade Crypto. The Returns Were Ugly. (Barrons.com)
07:00PM	Big Tech earnings, Fed meeting, Trump & Xi meet: What to Watch (Yahoo Finance Video)
10:00AM	Loading…
10:00AM	Analysts Estimate AbbVie (ABBV) to Report a Decline in Earnings: What to Look Out for (Zacks)
09:30AM	Wall Street Analysts Think AbbVie (ABBV) Is a Good Investment: Is It? (Zacks)
Oct-23-25 11:13AM	3 Pharmaceutical Growth Stocks to Buy and Hold for 10 Years (MarketBeat)
Oct-22-25 07:00PM	AbbVie: Navigating Challenges and Seizing Opportunities in the Pharma Sector (Motley Fool)
05:45PM	AbbVie (ABBV) Sees a More Significant Dip Than Broader Market: Some Facts to Know (Zacks)
03:44PM	Analyst Says He Likes AbbVie (ABBV) Amid 'Attractive' Valuation (Insider Monkey)
02:31PM	AbbVie Inc. (ABBV): A Bull Case Theory (Insider Monkey)
10:29AM	AbbVie Up More Than 30% in 6 Months: How to Play the Stock (Zacks)
09:00AM	Here is What to Know Beyond Why AbbVie Inc. (ABBV) is a Trending Stock (Zacks)
Oct-21-25 07:57PM	This 3 Stocks Portfolio Provides Monthly Income (Zacks)
04:17PM	Top Stock Reports for Apple, Meta Platforms & JPMorgan (Zacks)
03:19PM	Final Trades: Abbvie, Qualcomm, Aptiv, and Palo Alto Networks (CNBC TV)
12:07PM	AbbVie's Rinvoq Beats Humira in Key Arthritis Trial (GuruFocus.com)
08:00AM	The Confidence Project by BOTOX Cosmetic (onabotulinumtoxinA) Unveils This Year's Grant Recipients (PR Newswire)
Oct-20-25 10:10AM	Here's What to Expect From AbbVie's Oncology Segment in Q3 Earnings (Zacks)
08:00AM	Loading…
08:00AM	RINVOQ (upadacitinib) Demonstrated Superiority Versus HUMIRA (adalimumab) for Primary Endpoint in a Head-to-Head Study in Rheumatoid Arthritis Patients Who Have Failed First TNF Inhibitor (PR Newswire)
Oct-18-25 09:05AM	AbbVie completes acquisition of Gilgamesh Pharmaceuticals bretisilocin (TipRanks)
Oct-17-25 09:00AM	AbbVie Completes Acquisition of Gilgamesh Pharmaceuticals' Bretisilocin (PR Newswire)
Oct-16-25 06:45AM	Want Decades of Passive Income? 3 Stocks to Buy Now and Hold Forever. (Motley Fool)
01:49AM	Cantor Fitzgerald Reaffirms Overweight Rating on AbbVie (ABBV) (Insider Monkey)
Oct-15-25 05:45PM	AbbVie (ABBV) Stock Falls Amid Market Uptick: What Investors Need to Know (Zacks)
09:00AM	3 Top Dividend Growth Stocks to Buy Right Now (Motley Fool)
08:30AM	Enveric Biosciences hires Fish & Richardson to defend patent tied to AbbVie deal (Investing.com)
Oct-14-25 11:09AM	Can Rinvoq and Skyrizi Sales Drive Another Strong Quarter for AbbVie? (Zacks)
Oct-13-25 01:49PM	Final Trades: Abbvie, Amazon, Datadog and Sixth Street Specialty Lending (CNBC TV)
01:40PM	AZN Strikes Drug Pricing Deal With Trump, Gets 3-Year Tariff Reprieve (Zacks)
10:57AM	U.S. Food and Drug Administration (FDA) Approves Updated Indication Statement for RINVOQ (upadacitinib) for the Treatment of Inflammatory Bowel Disease (PR Newswire)
09:53AM	2 Dividend Stocks to Double Up on Right Now (Motley Fool)
07:15AM	AbbVie to Present New Data at ESMO 2025 Reinforcing Leadership in Advancing Targeted Therapies for Solid Tumors (PR Newswire)
Oct-10-25 09:00AM	Is Trending Stock AbbVie Inc. (ABBV) a Buy Now? (Zacks)
02:59AM	What to Expect From AbbVie's Q3 2025 Earnings Report (Barchart)
Oct-09-25 10:14AM	AbbVie vs. Eli Lilly: Which Large Drugmaker Has the Edge in 2025? (Zacks)
08:00AM	SkinMedica Debuts Reimagined Packaging and Unveils New HA5 Hydra Collagen Water Burst Moisturizer (PR Newswire)
02:05AM	How pharma giant AbbVie holds leaders accountable for culture (Fortune)
Oct-08-25 10:22AM	Cramer's 'Absolute Favorite' AbbVie Rises After Study Completions and Upgrade (Insider Monkey)
10:03AM	AbbVie Inc. (ABBV) Starts Building $70 Million Expansion of Its AbbVie Bioresearch Centre in Worcester, Massachusetts (Insider Monkey)
07:16AM	Why AbbVie and Johnson & Johnson Could Outperform Pfizer (MarketBeat)
03:41AM	Why AbbVie Stock Soared in September (Motley Fool)
Oct-07-25 04:44AM	3 Dividend Stocks to Double Up On Right Now (Motley Fool)
Oct-06-25 05:25PM	3 Exceptional Stocks to Build Long-Term Wealth (MarketBeat)
01:57PM	Eli Lilly Stock Rises 16% in a Week: Here's What You Should Know (Zacks)
10:11AM	AbbVie Stock on the Move: What Sparked the 6% Jump in the Past Week? (Zacks)
09:03AM	Zacks Value Trader Highlights: Pfizer, Merck, AbbVie, Eli Lilly and Novo Nordisk (Zacks)
09:00AM	AbbVie Announces Positive Topline Results from Phase 2 ELATE Trial Evaluating OnabotulinumtoxinA (BOTOX) for the Treatment of Upper Limb Essential Tremor (PR Newswire)
08:32AM	How J&J's Innovative Medicines Segment is Poised Ahead of Q3 Results (Zacks)
Oct-03-25 04:55PM	5 Large Cap Drug Stocks: Values or Traps? (Zacks)
04:21PM	How BeOne Medicines, An IBD 50 Stock, Is Taking On Big Names In Cancer Treatment (Investor's Business Daily)
09:59AM	Is PFE Stock a Buy After 14% Rise Post Drug Pricing Deal With Trump? (Zacks)
06:27AM	Bernstein Remains a Hold on AbbVie Inc. (ABBV) (Insider Monkey)
12:38AM	2 Healthcare Stocks to Research Further and 1 Facing Challenges (StockStory)
Oct-02-25 05:45PM	AbbVie (ABBV) Stock Sinks As Market Gains: Here's Why (Zacks)
09:23AM	Stock Market News for Oct 2, 2025 (Zacks)
08:00AM	AbbVie to Host Third-Quarter 2025 Earnings Conference Call (PR Newswire)
02:55AM	AbbVie (ABBV) Advances Parkinson's Treatment With Tavapadon NDA (Insider Monkey)
02:08AM	Leerink Raises AbbVie (ABBV) Price Target on Strong Business Performance (Insider Monkey)
Oct-01-25 06:36PM	Why AbbVie Stock Cruised to an Almost 6% Gain Today (Motley Fool) +5.55%
04:01PM	Why AbbVie (ABBV) Stock Is Trading Up Today (StockStory)
01:57PM	AbbVie's (ABBV) Dividend Track Record: A Testament to Stability (Insider Monkey)
11:37AM	AbbVie breaks ground on $70m US biologics site amid Trump pressure (Pharmaceutical Technology)
10:15AM	AbbVie Stock Is Just What the Doctor Ordered (Barchart)
09:22AM	Company News for Oct 1, 2025 (Zacks)
08:00AM	Natrelle Awarded Supplier Agreement from Vizient (PR Newswire)
05:31AM	Bristol Myers, Takeda to pool data for AI-based drug discovery (Reuters)
05:25AM	Want Decades of Passive Income? 3 Stocks to Buy Now and Hold Forever (Motley Fool)
Sep-30-25 04:05PM	AbbVie, AMN Healthcare Services, LeMaitre, Waters Corporation, and Organon Shares Skyrocket, What You Need To Know (StockStory)
03:00PM	AbbVie Begins Construction on $70 Million Expansion to Further Increase Biologics Manufacturing and R&D Presence in the U.S. (PR Newswire)
11:47AM	Pfizer Stock Rises After WSJ Reports Company Will Cut Drug Costs (The Wall Street Journal)
04:00AM	AbbVie Inc.(ABBV) Unit Expands Skin Solution Availability amid $5.2B Opportunity (Insider Monkey)
Sep-29-25 02:36PM	AbbVie Seeks FDA Nod for Tavapadon to Treat Parkinson's Disease (Zacks)
12:00PM	AbbVie Breaks Ground on New North Chicago Active Pharmaceutical Ingredient Manufacturing Facility (PR Newswire)
09:11AM	AbbVie to launch ovarian cancer drug in UK at US price (Reuters)
09:00AM	AbbVie Inc. (ABBV) is Attracting Investor Attention: Here is What You Should Know (Zacks)
09:00AM	AbbVie Announces UK Pricing Strategy for ELAHERE (mirvetuximab soravtansine-gynx) (PR Newswire)
04:42AM	1 Top ETF I Wouldn't Hesitate to Invest $1,000 Into Right Now (Motley Fool)
Sep-28-25 10:00AM	5 Dividend Powerhouses to Buy and Never Sell (Motley Fool)
Sep-26-25 04:51PM	Eli Lilly, Pfizer, Amgen Stocks Rise After Trumps 100% Pharma Tariff Threat. Heres Why. (Barrons.com)
11:45AM	Has AbbVie Successfully Navigated Top-line Growth Post Humira LOE? (Zacks)
09:58AM	Trump's new tariffs on pharma, furniture, & trucks: What to know (Yahoo Finance Video)
08:45AM	AbbVie Submits New Drug Application to U.S. FDA for Tavapadon for the Treatment of Parkinson's Disease (PR Newswire)
08:15AM	Eli Lilly, Pfizer Stocks Rise After Trump's 100% Pharma Tariff Threat. Here's Why. (Barrons.com)
Sep-25-25 05:00AM	Allergan Aesthetics to Showcase Multimodal Treatment Approach and Continued Commitment to Skin Quality at AMWC Dubai (PR Newswire)
05:00AM	3 Top Dividend Stocks to Buy and Hold Forever (Motley Fool)
04:44AM	Where Will AbbVie Be in 5 Years? (Motley Fool)
Sep-24-25 05:45PM	AbbVie (ABBV) Declines More Than Market: Some Information for Investors (Zacks)
Sep-23-25 02:47PM	These Dividend Stocks Have Big Yields and Are Beating the Odds (Barrons.com)

AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products. It focuses on treating conditions such as chronic autoimmune diseases in rheumatology, gastroenterology, and dermatology, oncology, including blood cancers, virology, hepatitis C virus (HCV) and human immunodeficiency virus (HIV), neurological disorders, such as Parkinson's, metabolic, comprising thyroid disease and complications associated with cystic fibrosis, pain associated with endometriosis, and other serious health conditions. The company was founded on October 19, 2011 and is headquartered in North Chicago, IL.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Richard A. Gonzalez	Former Director	Aug 22 '25	Proposed Sale	210.84	62,755	13,231,264		Aug 22 06:02 PM
Richard A. Gonzalez	Former Director	Aug 21 '25	Proposed Sale	211.04	90,000	18,993,948		Aug 21 06:04 PM
SALEKI-GERHARDT AZITA	EVP, CHIEF OPERATIONS OFFICER	Aug 12 '25	Option Exercise	54.86	42,370	2,324,418	219,662	Aug 14 05:00 PM
SALEKI-GERHARDT AZITA	EVP, CHIEF OPERATIONS OFFICER	Aug 12 '25	Sale	198.42	42,370	8,407,055	177,292	Aug 14 05:00 PM
AZITA SALEKI-GERHARDT	Officer	Aug 12 '25	Proposed Sale	198.42	42,370	8,407,068		Aug 12 07:22 PM
Richard A. Gonzalez	Former Director	Aug 01 '25	Proposed Sale	195.83	61,500	12,043,268		Aug 08 05:03 PM
Donoghoe Nicholas	EVP, CHIEF BUS/STRAT OFFICER	Aug 05 '25	Sale	198.51	13,295	2,639,253	58,247	Aug 07 05:00 PM
NICHOLAS DONOGHOE	Officer	Aug 05 '25	Proposed Sale	198.51	13,299	2,639,966		Aug 05 04:40 PM
Stewart Jeffrey Ryan	EVP, CHIEF COMMERCIAL OFFICER	Mar 31 '25	Option Exercise	79.02	25,700	2,030,814	112,066	Apr 02 05:00 PM
Stewart Jeffrey Ryan	EVP, CHIEF COMMERCIAL OFFICER	Mar 31 '25	Sale	210.08	58,832	12,359,504	53,234	Apr 02 05:00 PM
Stewart Jeffrey Ryan	Officer	Mar 31 '25	Proposed Sale	210.09	58,832	12,359,897		Mar 31 05:30 PM
Reents Scott T	EVP, CHIEF FINANCIAL OFFICER	Mar 14 '25	Sale	212.34	17,644	3,746,527	11,577	Mar 18 05:00 PM
Reents Scott T	Officer	Mar 14 '25	Proposed Sale	212.35	17,644	3,746,628		Mar 14 04:34 PM
GONZALEZ RICHARD A	Director	Feb 28 '25	Sale	205.11	92,460	18,964,471	395,097	Mar 04 05:00 PM
GONZALEZ RICHARD A	Director	Mar 03 '25	Sale	210.53	6,168	1,298,549	388,929	Mar 04 05:00 PM
Siatis Perry C	EVP, GC AND SECRETARY	Mar 03 '25	Option Exercise	159.88	18,008	2,879,040	22,627	Mar 04 05:00 PM
Siatis Perry C	EVP, GC AND SECRETARY	Mar 03 '25	Sale	210.00	18,008	3,781,680	4,619	Mar 04 05:00 PM
Siatis Perry C	EVP, GC AND SECRETARY	Feb 28 '25	Sale	206.30	9,892	2,040,722	4,619	Mar 04 05:00 PM
RICHMOND TIMOTHY J.	EVP, CHIEF HR OFFICER	Mar 03 '25	Sale	210.45	21,250	4,472,039	6,130	Mar 04 05:00 PM
GONZALEZ RICHARD A	Officer	Mar 03 '25	Proposed Sale	210.53	6,168	1,298,550		Mar 03 05:57 PM
PERRY C SIATIS	Officer	Mar 03 '25	Proposed Sale	210.00	18,008	3,781,680		Mar 03 04:28 PM
TIMOTHY RICHMOND	Officer	Mar 03 '25	Proposed Sale	210.46	21,250	4,472,184		Mar 03 04:08 PM
GONZALEZ RICHARD A	Officer	Feb 28 '25	Proposed Sale	205.11	92,460	18,964,882		Feb 28 05:37 PM
Buckbee Kevin K	SVP, CONTROLLER	Feb 26 '25	Option Exercise	98.48	16,260	1,601,313	28,906	Feb 28 05:00 PM
Buckbee Kevin K	SVP, CONTROLLER	Feb 26 '25	Sale	203.41	18,944	3,853,372	11,496	Feb 28 05:00 PM
RICHMOND TIMOTHY J.	EVP, CHIEF HR OFFICER	Feb 26 '25	Option Exercise	114.36	22,210	2,539,936	66,494	Feb 28 05:00 PM
RICHMOND TIMOTHY J.	EVP, CHIEF HR OFFICER	Feb 26 '25	Sale	202.90	29,917	6,070,036	44,284	Feb 28 05:00 PM
PERRY C SIATIS	Officer	Feb 28 '25	Proposed Sale	206.31	9,892	2,040,790		Feb 28 04:12 PM
Buckbee Kevin K	Officer	Feb 26 '25	Proposed Sale	203.41	18,944	3,853,398		Feb 26 05:47 PM
TIMOTHY RICHMOND	Officer	Feb 26 '25	Proposed Sale	202.90	29,917	6,070,176		Feb 26 04:04 PM
Siatis Perry C	EVP, GC AND SECRETARY	Feb 20 '25	Sale	197.90	5,778	1,143,453	22,381	Feb 24 05:00 PM
PERRY C SIATIS	Officer	Feb 20 '25	Proposed Sale	197.90	5,778	1,143,492		Feb 20 04:10 PM
Buckbee Kevin K	SVP, CONTROLLER	Dec 16 '24	Option Exercise	93.50	1,800	168,300	8,783	Dec 18 05:00 PM
Buckbee Kevin K	SVP, CONTROLLER	Dec 16 '24	Sale	172.24	1,800	310,032	6,983	Dec 18 05:00 PM
Buckbee Kevin K	Officer	Dec 16 '24	Proposed Sale	172.25	1,800	310,045		Dec 16 05:34 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

ABBV

Abbvie Inc

Upgrade your FINVIZ experience